logo-loader

Full interview: Humanigen plans Phase III clinical trial for lenzilumab to treat symptoms of coronavirus patients

Published: 10:41 23 Mar 2020 EDT

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive the firm wants to carry out a Phase III clinical trial for its lenzilumab to treat cytokine storm, which can lead to acute respiratory distress syndrome (ARDS), which is associated with the current coronavirus pandemic.

Durrant says additionally, lenzilumab is available for physicians who request it through compassionate use immediately.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

22 minutes ago